Drug Profile
AT20 KLH
Alternative Names: AIDS vaccine - Medestea; AT20-KLH; HIV vaccine - Medestea; p17 based immunogen - MedesteaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Medestea
- Class Peptide vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections in Italy (IM, Injection)
- 05 Jan 2016 Medestea completes a phase I trial in HIV infections in Italy before January 2016